Core Viewpoint - The establishment of the first clinical and translational ward for brain-computer interface (BCI) technology in China aims to transition BCI development from research-driven to clinically-driven applications [1][3][4]. Group 1: Clinical and Research Collaboration - The ward is a collaborative effort led by Beijing Tiantan Hospital, involving multiple research institutions such as Tsinghua University and the Chinese Academy of Sciences [3]. - It will conduct clinical trials for the "Beijing Brain No. 1" BCI device and establish a collaborative innovation system integrating medical, engineering, research, production, and government sectors [3][4]. Group 2: Training and Standards Development - The ward will organize nationwide multi-center clinical trials and develop ethical guidelines, admission standards, and clinical pathway guidelines for BCI technology [3][4]. - It aims to create a training platform for clinical doctors, engineering technicians, and researchers, fostering talent development in the BCI field [3][4]. Group 3: Technological Integration and Patient Care - The ward will feature an integrated BCI technology platform with advanced equipment for patient assessment, regulation, and training, focusing on improving the quality of life for patients with severe conditions [4]. - The goal is to transition BCI technology from prototypes to bedside applications, enhancing patient outcomes through innovative solutions [4]. Group 4: Future Vision and Impact - The director of the National Clinical Research Center for Neurological Diseases emphasized the importance of BCI as a key entry point for future medicine, aiming for breakthroughs that benefit the public [4]. - The hospital's leadership expressed commitment to leveraging its platform to transform high-level innovations into quality healthcare services, addressing public demand for improved health outcomes [4].

截至目前，公司已经拥有核心技术授权发明专利十余项，二类医疗器械注册证一张。 #核心产品介绍 此次融资由 广州同新基金、平云创科基金、深担创投、广州创投母基金、源起基金、京津冀技术创新中心以及广东协同创新控股 等多家投资机构联合投资， 资金将主要用于推动析芒医疗在脑机接口领域的技术研发与创新，特别是加速脑机接口医疗器械和关键元器件的研发工作。 除此之外，资金将用于临床试验、器械注册、市场推广及人才梯队的建设，为公司在全球脑机接口领域的竞争力提供支持。 #析芒医疗 析芒医疗成立于2022年10月，公司创始团队拥有近20年的微型医疗器械和生物芯片领域的研发经验，核心成员汇聚了包括北京大学、香港科技大学、伊利诺伊理工 大学在内的国内外顶尖学府培养的专家学者及技术人员，在微型器械、生物芯片和神经科学方面拥有深厚的学术背景和研发经验，掌握植入式神经电极和专用神经 信号处理系统等脑机接口核心技术，专注于为神经功能障碍和神经损伤患者提供前沿的医疗解决方案。 2025年1月25日， 广州析芒医疗科技有限公司（以下简称"析芒医疗"） 宣布，已完成 数千万人民币的天使轮及天使+轮融资 。 析芒医疗的核心产品分为医疗产品和科研产品两 ...